Profit before tax (PBT) dropped 70.98% YoY to Rs 552.6 crore in Q1 FY27.
EBITDA slipped 55.72% to Rs 1,008.8 crore in Q1 FY27 compared with Rs 2,278.4 crore in Q1 FY26. EBITDA margin contracted to 12.5% in Q1 FY27 as against 26.7% in Q1 FY26.
Revenue from the Global Generics segment declined 4.79% year-on-year to Rs 7,199.3 crore during the quarter.
Revenue from the North America business fell 35.38% YoY to Rs 2,204.8 crore, mainly due to lower sales of Lenalidomide. The company launched six new products in the region during the quarter.
Revenue from the India business increased 16.76% YoY to Rs 1,717.7 crore, supported by new brand launches, including innovative assets and recently acquired portfolios, along with price increases and higher sales volumes. The company launched seven new brands during the quarter.
Revenue from the Europe region grew 13.30% YoY to Rs 1,444 crore, aided by the launch of 24 new generic products.
The Emerging Markets segment reported a 30.52% YoY growth in revenue to Rs 1,832.8 crore, driven by new launches, higher volumes and favourable foreign exchange movement.
Research and Development (R&D) expenditure stood at Rs 580 crore in Q1 FY27, down 8% year-on-year but up 6% sequentially. R&D expenses accounted for 7.1% of revenue during the quarter, compared with 7.3% in Q1 FY26. The decline was primarily due to lower development spending on biosimilars, while investments remained focused on complex generics, including peptides and biosimilars.
Co-Chairman & MD, G V Prasad, said: Our Q1 FY27 performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide API. However, our underlying base business continued to deliver healthy doubledigit growth across all key geographies. Our focus remains on improving the health of our base business through disciplined execution and operational excellence, while building our future pipeline of peptides, biosimilars, and innovative assets to deliver long-term growth.
Meanwhile, the company's board approved the appointment of Dr Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel and her induction as a member of the Management Council, effective 22 July 2026.
Hyderabad-based Dr Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.
The scrip slipped 1.95% to settle at Rs 1,183 on the BSE.
Powered by Capital Market - Live News
Beware of fraudulent tips, unauthenticated news and advice on stock market.
At BOB Capital, your account security is our topmost priority. Beware of receiving fraudulent communications, unauthenticated trading tips and unsolicited calls on trading in stocks from unverified sources received through WhatsApp, Telegram, SMS, Calls, etc., and take an informed decision before investing.
Report unsolicited messages to the Stock Exchange on +91 8291833676 or email: feedbk_invg@nse.co.in
Please visit here to understand better.
Please visit CVC website at pledge.cvc.nic.in and take "Integrity Pledge" to be an active part of the "Satark Bharat, Samriddh Bharat" (Vigilant India, Prosperous India).
Filing complaints on SCORES - Easy & quick: a. Register on SCORES portal scores.sebi.gov.in/ b. Mandatory details for filing complaints on SCORES are i. Name, PAN, Address, Mobile Number, E-mail ID. c. Benefits: i. Effective communication ii. Speedy redressal of the grievances.
Valued Customer,
BOB Capital Markets Limited (BOBCaps) is firmly committed to the safety of your wealth. We would like to bring to your notice certain precautions that you certainly must take against potential tele-fraudsters/ unscrupulous and unregistered portfolio managers:
ALWAYS AVOID
We would like to caution you against such fraudulent calls and SMSes and urge you to be alert. Follow the golden rule:
Do not share your Login Credentials or Passwords with anybody
BOBCaps employees / representatives never ask for your password.
Certain tele-fraudsters / unscrupulous and unregistered portfolio managers call customers or SMS them on the pretext of providing investment tips and lure them to invest through their bogus firms by promising huge profits.
Such deceitful callers ask the customer to share his/her login credentials with passwords to allow trading in their accounts, assuring huge returns.
Often trades done in the customer’s accounts are far from the best interest of the customers. Holdings of customers are often sold and with the funds, trades are then placed in illiquid securities at unrealistic prices.
At times, the holdings of customers are sold at prices detrimental to the customer. The so-called “portfolio manager” assures profits, which naturally does not materialize. Customers are deceived into providing access to their trading accounts, thereby allowing such fraudsters access to funds and securities available to execute trades, injurious to the customer’s interest.
In our continuous effort to keep you safeguard from the market related frauds and increase awareness while conducting trades, we request you to go through the Press Release issued by the NSE and would request you to ensure that you do not engage with the individuals and entities mentioned below: